Skip to main content

Table 2 Molecular and clinical characteristics of patients with primary myelofibrosis (PMF)

From: A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients

VariablesCALR mutation (n = 19)JAK2 mutation (n = 23)Triple Negative (n = 3)p-value
Males (%)13 (68.4)14 (60.9)1 (33.3)0.025*
Age,
Median (Range)
45 (37–70)53 (21–76)43 (22–60)0.138
Haemoglobin (g/dL),
Median (Range)
10.5 (9.5–13.4)9.8 (6.6–15)7.9 (6.5–14.2)0.45
TLC ×109/L,
Median (Range)
9.8 (5.6–63.2)11.9 (1.8–22.1)40.9 (15.1–25)0.075
Platelet × 109/L,
Median (Range)
273 (122–1147)382.5 (12–239)131.5 (38–483)0.358
Circulating blasts (%),
Median (Range)
2947.5 (44–51)380.306
Reticulin Fibrosis
MF 0000 
MF 15 (26.3)15 (65.2)2 (66.7)0.067
MF 214 (73.7)8 (34.8)1 (33.3) 
Constitutional symptoms (%)12 (63.2)14 (60.9)3 (100)0.421
DIPSS score, (%):
 Low4 (21.1)00 
 Intermediate-12 (10.5)5 (21.7)00.259
 Intermediate-29 (47.4)15 (65.2)3 (100) 
 High4 (21.1)3 (13)0 
Leukemic transformation, (%)2 (10.5)2 (8.7)1 (33.3)0.629
  1. *significant